FR14C0033I1 - - Google Patents

Info

Publication number
FR14C0033I1
FR14C0033I1 FR14C0033C FR14C0033I1 FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1 FR 14C0033 C FR14C0033 C FR 14C0033C FR 14C0033 I1 FR14C0033 I1 FR 14C0033I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR14C0033I1 publication Critical patent/FR14C0033I1/fr
Application granted granted Critical
Publication of FR14C0033I2 publication Critical patent/FR14C0033I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
FR14C0033C 2001-10-04 2014-04-16 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS Active FR14C0033I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
FR14C0033I1 true FR14C0033I1 (en) 2014-06-13
FR14C0033I2 FR14C0033I2 (en) 2014-11-14

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0033C Active FR14C0033I2 (en) 2001-10-04 2014-04-16 PHENYL-PIPERAZINE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS

Country Status (39)

Country Link
US (10) US7144884B2 (en)
EP (2) EP1436271B3 (en)
JP (3) JP3896116B2 (en)
KR (3) KR100842702B1 (en)
CN (1) CN1319958C (en)
AR (2) AR036659A1 (en)
AT (2) ATE441631T1 (en)
AU (2) AU2002333220C1 (en)
BE (1) BE2014C036I2 (en)
BR (3) BR122012009534C8 (en)
CA (1) CA2462110C (en)
CO (1) CO5580746A2 (en)
CY (3) CY1107924T1 (en)
DE (2) DE60225162T3 (en)
DK (2) DK1749818T3 (en)
EA (2) EA011096B1 (en)
EG (1) EG25095A (en)
ES (2) ES2298425T7 (en)
FR (1) FR14C0033I2 (en)
HK (1) HK1072600A1 (en)
HR (1) HRP20040220A2 (en)
HU (3) HU230189B1 (en)
IL (1) IL160655A0 (en)
IS (2) IS2578B (en)
LT (1) LTC1436271I2 (en)
LU (1) LU92397I2 (en)
ME (1) ME00039B (en)
MX (1) MXPA04002959A (en)
MY (1) MY140950A (en)
NL (1) NL300652I1 (en)
NO (3) NO326443B1 (en)
NZ (1) NZ531556A (en)
PL (2) PL209253B1 (en)
PT (2) PT1749818E (en)
RS (2) RS52326B (en)
SI (1) SI1436271T1 (en)
UA (2) UA81749C2 (en)
WO (1) WO2003029232A1 (en)
ZA (1) ZA200401583B (en)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
UA81472C2 (en) * 2003-04-04 2008-01-10 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
ATE392896T1 (en) * 2003-04-04 2008-05-15 Lundbeck & Co As H 4-(2-PHENYLOXYPHENYL)-PIPERIDINE OR -1,2,3,6-TETRAHYDROPYRIDINE DERIVATIVES AS SEROTONIN REUPPOST INHIBITORS
UA81469C2 (en) * 2003-04-04 2008-01-10 Lundbeck & Co As H 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
BRPI0417858B1 (en) 2003-12-23 2017-10-10 H. Lundbeck A/S DERIVATIVE COMPOUNDS OF ANILINE AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT
AR052308A1 (en) * 2004-07-16 2007-03-14 Lundbeck & Co As H DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARILAMINE AND A PHARMACEUTICAL COMPOSITION CONTAINING THE COMPOUND
DE602006007550D1 (en) 2005-02-10 2009-08-13 Neurosearch As ALKYL SUBSTITUTED HOMOPIPERAZINE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RECOVERY INHIBITORS
AR054393A1 (en) 2005-06-17 2007-06-20 Lundbeck & Co As H DERIVATIVES OF BENZO (B) FURANO AND BENZO (B) THIOPHEN, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF THE REINFORCEMENT OF AMINA BOSS NEUTRANTS.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054394A1 (en) * 2005-06-17 2007-06-20 Lundbeck & Co As H DERIVATIVES OF 2- (1H-INDOLILSULFANIL) -ARIL AMINA
JP2007106746A (en) * 2005-09-13 2007-04-26 Tosoh Corp New aryl homopiperazine compounds, or their salt and production method
ZA200809917B (en) * 2006-06-16 2010-08-25 Lundbeck & Co As H Crystalline forms of 4- [2-(4-Methylphenylsulfanyl) - Phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
WO2007144006A1 (en) * 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
JP7179035B2 (en) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for treating cognitive impairment Piperazine
RS51687B (en) * 2006-06-16 2011-10-31 H. Lundbeck A/S. Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
BR122020011920A2 (en) * 2006-06-16 2020-08-25 Lundbeck & Co As H compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (en) * 2007-03-20 2013-08-21 Lundbeck & Co As H Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine
TWI432194B (en) * 2007-03-20 2014-04-01 Lundbeck & Co As H Novel therapeutic uses of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine
SI2167085T1 (en) * 2007-06-15 2014-05-30 H. Lundbeck A/S 4- š2- (4-methylphenylsulfanyl) phenylćpiperidine for the treatment of irritable bowel syndrome (ibs)
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) † 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
EP2358675B9 (en) 2008-11-14 2019-09-11 Theravance, Inc. 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
JP5722879B2 (en) * 2009-04-24 2015-05-27 ハー・ルンドベック・アクチエゼルスカベット Liquid formulation of 1- [2- (2,4-dimethylphenylsulfanyl) phenyl] piperazine salt
CN102639117A (en) * 2009-08-24 2012-08-15 H.隆德贝克有限公司 New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN102741226B (en) * 2009-10-30 2016-01-06 詹森药业有限公司 -2-phenoxy group-aniline δ opioid receptor conditioning agent that 4-replaces
EP2523945A1 (en) * 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
JP5769348B2 (en) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 1- (2-phenoxymethylheteroaryl) piperidine compound and 1- (2-phenoxymethylheteroaryl) piperazine compound
MY162392A (en) * 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
US8920840B2 (en) * 2010-04-30 2014-12-30 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (en) 2010-07-14 2012-01-18 Sandoz Ag Crystalline compound of1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol and lactic acid
TW201212918A (en) * 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
ES2939477T3 (en) 2011-06-20 2023-04-24 H Lundbeck As Deuterated 1-Piperazino-3-phenyl-indanes for the treatment of schizophrenia
IN2014DN04226A (en) 2011-11-14 2015-05-22 Gen Hospital Corp
KR102008039B1 (en) 2012-01-03 2019-08-06 하. 룬드벡 아크티에셀스카브 Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
EP2897943B1 (en) 2012-09-19 2019-04-24 Sandoz AG Crystalline form of vortioxetine hydrobromide
EP2931276B1 (en) 2012-12-13 2018-02-21 H. Lundbeck A/S Compositions comprising vortioxetine and donepezil
EP2958903B1 (en) 2013-02-22 2017-04-12 H. Lundbeck A/S Vortioxetine manufacturing process
EP3495347A1 (en) 2013-04-04 2019-06-12 LEK Pharmaceuticals d.d. New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
CN104109135B (en) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2- (2,4- dimethylphenylsulfanyls)-Ben Ji ]The preparation method of piperazine
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (en) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 For preparing 4（2‑（4 aminomethyl phenyl sulfenyls））Compound, its preparation method and the application of Phenylpiperidine
RU2679661C1 (en) 2013-12-20 2019-02-12 Х. Лундбекк А/С Use of opioid receptor antagonist with k-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (en) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 The fertile preparation method for Xi Ting
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (en) 2014-05-30 2016-05-04 镇江圣安医药有限公司 Derivative and pharmaceutical composition and the purposes of [(benzene sulfanyl)-phenyl] piperazine
FR3023320B1 (en) * 2014-07-03 2017-03-10 Ifp Energies Now SYSTEM AND METHOD FOR STORING AND RECOVERING COMPRESSED GAS ENERGY WITH HEAT STORAGE USING A RADIAL EXCHANGER
CZ2014471A3 (en) 2014-07-08 2016-01-20 Zentiva, K.S. Process for preparing vortioxetine
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (en) * 2014-07-24 2014-11-19 李雪梅 Vortioxetine hydrobromide injection
CN104292183B (en) * 2014-09-29 2016-01-06 杨献美 A kind of antidepressant drug irrigates the preparation method for Xi Ting
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (en) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 Hydrobromic acid irrigates the preparation method for western spit of fland beta crystal
CN104586756A (en) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 Oral solution containing vortioxetine and preparation method thereof
CZ201531A3 (en) 2015-01-21 2016-08-03 Zentiva, K.S. Polymer-stabilized amorphous forms of vortioxetine
CN104610195B (en) * 2015-01-30 2017-06-27 上虞京新药业有限公司 The aspartate of Vortioxetine or its hydrate and its production and use
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
US10227317B2 (en) 2015-02-25 2019-03-12 Lupin Limited Process for the preparation of vortioxetine
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN104829557B (en) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 A kind of noval chemical compound 1 [2（2,4 3,5-dimethylphenyl sulfenyls）Phenyl] 2 oxygen piperazines and preparation method thereof and the application in Vortioxetine synthesis
JO3456B1 (en) 2015-05-13 2020-07-05 H Lundbeck As Vortioxetine pyroglutamate
MX2018000657A (en) 2015-07-17 2018-09-06 Pasteur Institut 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation.
EP3337789A1 (en) * 2015-08-19 2018-06-27 Amneal Pharmaceuticals Company GmbH Process for preparation of vortioxetine hydrobromide
EP3362058B1 (en) * 2015-10-14 2021-09-01 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105348204B (en) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1- heterocycles -2- (Heteroarylthio) benzene derivatives and its application method and purposes
CN105461635B (en) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 Phenylpiperazine derivatives and its application method and purposes
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
CN109310691A (en) 2016-07-01 2019-02-05 H.隆德贝克有限公司 For quickly starting the dosage regimen of antidepressant effect
CN110022869A (en) 2016-07-15 2019-07-16 巴斯德研究院 For skin and/or the serotonin 1B receptor stimulators of hair reparation
CN109890799A (en) * 2016-07-22 2019-06-14 江苏恩华络康药物研发有限公司 Vortioxetine analog and application thereof and preparation
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (en) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 Vortioxetine intermediate impurities and its production and use
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (en) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 Phenyloctahydro-1H-pyrido [1,2-a ] pyrazine derivatives and uses thereof
CN108409729B (en) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 Phenyloctahydro-1H-pyrido [1,2-a ] pyrazine derivatives and uses thereof
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
EP3585388A4 (en) 2017-02-23 2020-08-12 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
HUE057993T2 (en) 2017-04-25 2022-06-28 H Lundbeck As Process for the manufacture of vortioxetine hbr alpha-form
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (en) 2017-07-07 2019-09-27 영진약품 주식회사 Novel 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine salt and method for preparing the same
CN107915685A (en) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 A kind of preparation method of hydrobromic acid Vortioxetine intermediate
CN108017595A (en) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 A kind of preparation method of 1- [2- (2,5- dimethyl benzenes sulfenyl) phenyl] piperazine
US11198671B2 (en) 2018-06-20 2021-12-14 Vio Ag Pharmaceuticals S.A. One-pot organo-pseudocatalytic C—H activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108863986B (en) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 Difluoromethyl-substituted phenylpiperazine derivatives and uses thereof
CN108727393B (en) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 Phenyl diazabicyclo derivative and application thereof
AU2021246973A1 (en) 2020-04-03 2022-11-03 H. Lundbeck A/S 1-(2-(2,4-dimethylphenylsulfanyl)-phenyl)piperazine for prevention or treatment of emotional blunting
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151755B1 (en) 1971-04-13 1973-11-19
CS151753B1 (en) 1971-04-13 1973-11-19
CS151751B1 (en) 1971-04-13 1973-11-19
CS151752B1 (en) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (en) 1987-07-29 1989-02-01 Ferrer Int 1-[2-(Phenylmethyl)phenyl]-piperazine compounds, a process for preparing them and pharmaceutical compostions containing them.
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
CA2185984C (en) * 1995-01-23 2007-12-04 Hirokazu Annoura Medicament for the alleviation or treatment of symptom derived from ischemic disease and compound useful therefor
CZ293595A3 (en) 1995-11-09 1999-12-15 Farmak A. S. Derivatives of n,n-dimethyl-2-(arylthio)benzylamine, their salts, processes of their preparation and their use in medicaments
FR2757160B1 (en) * 1996-12-13 1999-03-12 Sanofi Sa 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69828317T2 (en) * 1997-10-31 2005-05-25 Daiichi Suntory Pharma Co., Ltd. Process for the preparation of N - ((4-phenyl) methylphenyl) piperazines
WO2000059878A2 (en) 1999-04-02 2000-10-12 Icos Corporation INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF
EP1204645A2 (en) 1999-08-04 2002-05-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
IL148677A0 (en) * 1999-09-14 2002-09-12 Pharmacopeia Inc Article comprising a multi-channel dispensing head
CN1230432C (en) * 1999-12-30 2005-12-07 H·隆德贝克有限公司 Substituted phenyl-Piperazine derivatives, their preparation and use
JP2003519227A (en) * 1999-12-30 2003-06-17 ハー・ルンドベック・アクチエゼルスカベット Method for producing substituted benzene derivative
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (en) 2000-07-11 2002-05-16 Wolfgang Papenbrock Procedure for previewing websites
CA2432985A1 (en) 2001-01-23 2002-08-01 Vincent Mancuso Piperazine- and piperidine-derivatives as melanocortin receptor agonists
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (en) 2001-10-04 2008-02-11 Х. Луннбек А/С Derivated of phenylpiperazine as serotonin reuptake inhibitorS
IL161966A0 (en) * 2001-12-20 2005-11-20 Lundbeck & Co As H Aryloxyphenyl and arylsulfanylphenyl
AR043633A1 (en) 2003-03-20 2005-08-03 Schering Corp CANABINOID RECEIVERS LINKS
CA2521258C (en) * 2003-04-04 2009-12-01 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
BR122020011920A2 (en) * 2006-06-16 2020-08-25 Lundbeck & Co As H compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound

Also Published As

Publication number Publication date
AU2002333220C1 (en) 2023-10-05
CA2462110E (en) 2003-04-10
IL160655A0 (en) 2004-07-25
IS2732B (en) 2011-04-15
EA011096B1 (en) 2008-12-30
JP2005505585A (en) 2005-02-24
IS8806A (en) 2009-03-10
IS7164A (en) 2004-02-26
CA2462110C (en) 2010-05-11
KR20040047886A (en) 2004-06-05
MXPA04002959A (en) 2004-07-05
EP1749818B1 (en) 2009-09-02
KR20060118020A (en) 2006-11-17
CO5580746A2 (en) 2005-11-30
ME00039B (en) 2010-06-10
BE2014C036I2 (en) 2021-11-22
NO332355B1 (en) 2012-09-03
CY1107924T1 (en) 2013-09-04
EP1436271B3 (en) 2022-04-20
EA007537B3 (en) 2015-02-27
RS20120158A3 (en) 2013-10-31
ZA200401583B (en) 2005-05-25
FR14C0033I2 (en) 2014-11-14
US20060089368A1 (en) 2006-04-27
US20070060574A1 (en) 2007-03-15
JP3955614B2 (en) 2007-08-08
AU2002333220B2 (en) 2008-02-07
US9090575B2 (en) 2015-07-28
DE60225162T3 (en) 2022-08-11
MY140950A (en) 2010-02-12
US7144884B2 (en) 2006-12-05
AU2006215994A1 (en) 2006-10-05
BR122012009534B1 (en) 2018-02-27
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
HRP20040220A2 (en) 2005-02-28
AU2002333220A2 (en) 2003-04-14
CY2014022I2 (en) 2015-12-09
ATE386730T1 (en) 2008-03-15
HUP0402313A3 (en) 2010-03-29
US20050014740A1 (en) 2005-01-20
NL300652I2 (en) 2016-01-18
PL368442A1 (en) 2005-03-21
JP2007051149A (en) 2007-03-01
UA93857C2 (en) 2011-03-25
JP3896116B2 (en) 2007-03-22
EG25095A (en) 2011-08-17
HU230189B1 (en) 2015-09-28
HK1072600A1 (en) 2005-09-02
CN1319958C (en) 2007-06-06
BR122012009534C8 (en) 2021-05-25
BR122012023120B8 (en) 2022-01-18
AU2006215994A2 (en) 2006-10-05
PL209253B1 (en) 2011-08-31
KR100770194B1 (en) 2007-10-25
US10844029B2 (en) 2020-11-24
CN1561336A (en) 2005-01-05
US20110009423A1 (en) 2011-01-13
PT1436271E (en) 2008-04-10
PT1749818E (en) 2009-10-06
NO2014011I2 (en) 2015-08-31
JP2007031447A (en) 2007-02-08
EP1436271B1 (en) 2008-02-20
KR100842702B1 (en) 2008-07-01
US20060084662A1 (en) 2006-04-20
MEP6508A (en) 2010-02-10
HUS1400012I1 (en) 2020-12-28
IS2578B (en) 2010-02-15
BRPI0212733B8 (en) 2021-05-25
HU228956B1 (en) 2013-07-29
BR0212733B1 (en) 2014-05-13
JP3955613B2 (en) 2007-08-08
DK1436271T3 (en) 2008-06-09
EA007537B1 (en) 2006-10-27
LTC1436271I2 (en) 2016-09-12
EP1749818A2 (en) 2007-02-07
UA81749C2 (en) 2008-02-11
US7683053B2 (en) 2010-03-23
US8476279B2 (en) 2013-07-02
EP1436271A1 (en) 2004-07-14
AR066460A2 (en) 2009-08-19
BR122012023120B1 (en) 2017-03-21
US7138407B2 (en) 2006-11-21
DK1436271T6 (en) 2022-06-27
KR20070103515A (en) 2007-10-23
ES2298425T3 (en) 2008-05-16
NO20041628L (en) 2004-04-21
AR036659A1 (en) 2004-09-22
EP1749818A3 (en) 2008-04-02
DE60233608D1 (en) 2009-10-15
DE60225162T2 (en) 2009-02-12
ATE441631T1 (en) 2009-09-15
LU92397I2 (en) 2014-05-12
US8110567B2 (en) 2012-02-07
NO20083446L (en) 2004-04-21
ES2298425T7 (en) 2022-06-27
RS27704A (en) 2006-10-27
SI1436271T1 (en) 2008-06-30
NO326443B1 (en) 2008-12-08
NL300652I1 (en) 2016-01-18
AU2006215994A9 (en) 2006-10-05
RS20120158A2 (en) 2012-10-31
ES2328725T3 (en) 2009-11-17
HUP0402313A2 (en) 2005-02-28
US9708280B2 (en) 2017-07-18
BR0212733A (en) 2004-11-16
BR122012009534B8 (en) 2019-01-29
RS52865B (en) 2013-12-31
EA200400498A1 (en) 2004-08-26
US7148238B2 (en) 2006-12-12
DK1749818T3 (en) 2009-10-12
US20160137620A1 (en) 2016-05-19
DE60225162D1 (en) 2008-04-03
PL210551B1 (en) 2012-02-29
WO2003029232A1 (en) 2003-04-10
CY1110064T1 (en) 2015-01-14
US20180127389A1 (en) 2018-05-10
US20120302553A1 (en) 2012-11-29
CY2014022I1 (en) 2015-12-09
US20210276966A1 (en) 2021-09-09
AU2006215994B2 (en) 2008-11-13
EA200601269A1 (en) 2007-02-27
KR100783346B1 (en) 2007-12-07
NO2014011I1 (en) 2014-05-13
US20140163043A1 (en) 2014-06-12
CA2462110A1 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en)
BE2022C502I2 (en)
BE2022C547I2 (en)
BE2017C056I2 (en)
BE2017C051I2 (en)
BE2017C032I2 (en)
BE2016C051I2 (en)
BE2015C046I2 (en)
BE2014C052I2 (en)
BE2014C026I2 (en)
FR14C0033I1 (en)
BE2017C050I2 (en)
BE2011C034I2 (en)
BE2007C047I2 (en)
JP2002222957A5 (en)
JP2001285721A5 (en)
BE2014C008I2 (en)
BRPI0204884B1 (en)
CH1379220H1 (en)
BE2016C021I2 (en)
BE2017C059I2 (en)
HU0202285D0 (en)
JP2001225819A5 (en)
JP2002240658A5 (en)
BRPI0101486B8 (en)